Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in North Carolina: - Cone Health Cancer Center at Asheboro — Asheboro, North Carolina
- Randolph Hospital — Asheboro, North Carolina
- Cone Health MedCenter Asheboro — Asheboro, North Carolina
- Mission Hospital — Asheville, North Carolina
- AdventHealth Infusion Center Asheville — Asheville, North Carolina
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in North Carolina: - Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Pineville/LCI-Pineville — Charlotte, North Carolina
- Levine Cancer Institute-SouthPark — Charlotte, North Carolina
- Atrium Health University City/LCI-University — Charlotte, North Carolina
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in North Carolina: - Duke Cancer Center Cary — Cary, North Carolina
- Duke University Medical Center — Durham, North Carolina
- FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina
- Duke Cancer Center Raleigh — Raleigh, North Carolina
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in North Carolina: - Mission Hospital — Asheville, North Carolina
- Duke University Medical Center — Durham, North Carolina
- East Carolina University — Greenville, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in North Carolina: - Clinical Study Site — Chapel Hill, North Carolina
Phase 3 Recruiting Industry
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…
Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
- Levine Center — Charlotte, North Carolina
Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT04928846
Sites in North Carolina: - AdventHealth Hendersonville /ID# 265349 — Hendersonville, North Carolina
- FirstHealth of the Carolinas- Speciality Center /ID# 241279 — Pinehurst, North Carolina
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in North Carolina: - Novant Health Weisiger Cancer Insititute ( Site 0266) — Charlotte, North Carolina
- Novant Health Forsyth Medical Center ( Site 0166) — Winston-Salem, North Carolina
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in North Carolina: - Local Institution - 0624 — Asheville, North Carolina
- Local Institution - 0672 — Salisbury, North Carolina
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
- Wake Forest Baptist Health — Winston-Salem, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in North Carolina: - Southeastern Medical Oncology Center — Goldsboro, North Carolina
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in North Carolina: - Fletcher Hospital, Inc. dba AdventHealth Hendersonville — Hendersonville, North Carolina
Phase 3 Recruiting Industry
This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions for making proteins, and this change le…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
Phase 3 Recruiting Industry
This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enrolled participants will be randomized 2:…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in North Carolina: - Carolina Oncology Specialists — Hickory, North Carolina
Phase 3 Recruiting Industry
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet ch…
Sponsor: Amgen
NCT ID: NCT05920356
Sites in North Carolina: - Duke University — Durham, North Carolina
- FirstHealth Cancer Center — Pinehurst, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in North Carolina: - Atrium Health Wake Forest Baptist — Winston-Salem, North Carolina
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in North Carolina: - Rex Hematology Oncology Associates-Cary — Cary, North Carolina
- Durham VA Medical Center — Durham, North Carolina
- Rex Hematology Oncology Associates-Garner — Garner, North Carolina
- UNC Rex Healthcare — Raleigh, North Carolina
- UNC Rex Cancer Center of Wakefield — Raleigh, North Carolina
Phase 2 Recruiting NIH
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03191149
Sites in North Carolina: - Margaret R Pardee Memorial Hospital — Hendersonville, North Carolina
- FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in North Carolina: - Atrium Health — Charlotte, North Carolina
- Duke University Medical Center — Durham, North Carolina
- Regional Medical Oncology Center — Wilson, North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in North Carolina: - Local Institution - 2144 — Goldsboro, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in North Carolina: - Regional Medical Oncology Center — Wilson, North Carolina
Phase 2 Recruiting Industry
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…
Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in North Carolina: - University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 2 Recruiting Industry
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; th…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT06667908
Sites in North Carolina: - University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- FirstHealth of the Carolinas — Pinehurst, North Carolina
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in North Carolina: - Carolina BioOncology Institute — Huntersville, North Carolina
Phase 1, Phase 2 Recruiting Federal
Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients. Participants will receive either a combinati…
Sponsor: VA Office of Research and Development
NCT ID: NCT06681220
Sites in North Carolina: - Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC — Salisbury, North Carolina